Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096757 · ClinicalTrials.gov registry record · NA
The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention
A NA study of Peripheral Arterial Disease, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02096757: Completed NA study of Peripheral Arterial Disease, sponsored by University of California, San Francisco.
NCT02096757 is a NA study of Peripheral Arterial Disease that has completed, run by University of California, San Francisco. The registered enrollment target is 8 participants, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02096757, a NA study of Peripheral Arterial Disease, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators hypothesize that high-dose n-3 polyunsaturated fatty acids (PUFA) oral supplementation will improve will improve systemic inflammation and patency of peripheral vascular intervention (PVI).
Primary Outcome
Will reduce circulating pro-inflammatory markers (PIMs) and increase pro-resolution mediators (PRMs) assayed using targeted metabolo-lipidomics, increase PRM production within peripheral circulating monocytes.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Pro-Omega
- OTHER Pro-Omega Placebo
Study Locations (1)
California
- San Francisco Veterans Affairs Medical Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-06 |
| Est. Completion | 2017-03 |
| Phase | NA |
What the finished NCT02096757 record still lists
NCT02096757 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 2 interventions - of which Pro-Omega is the first listed.
NCT02096757 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02096757 about?
NCT02096757 is a clinical study titled "The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention". Investigators hypothesize that high-dose n-3 polyunsaturated fatty acids (PUFA) oral supplementation will improve will improve systemic inflammation and patency of peripheral vascular intervention (PVI).
What is the current status of trial NCT02096757?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2014-06. Estimated completion is 2017-03.
What conditions does trial NCT02096757 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT02096757?
The interventions under investigation include: Pro-Omega (DIETARY_SUPPLEMENT), Pro-Omega Placebo (OTHER).
Who is sponsoring clinical trial NCT02096757?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02096757 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02096757's enrollment target sits among peer trials
8 79th of 79 higher than 1 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
-
Prehabilitation and Rehabilitation in PAD
RECRUITING · NA
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
Assessment of the Utility of the Pantheris Small Vessel (SV) System
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia